LLY

885.52

+0.86%↑

JNJ

242.36

+0.87%↑

ABBV

213.25

+1.7%↑

NVS

150.37

+1.43%↑

MRK

117.85

-1.53%↓

LLY

885.52

+0.86%↑

JNJ

242.36

+0.87%↑

ABBV

213.25

+1.7%↑

NVS

150.37

+1.43%↑

MRK

117.85

-1.53%↓

LLY

885.52

+0.86%↑

JNJ

242.36

+0.87%↑

ABBV

213.25

+1.7%↑

NVS

150.37

+1.43%↑

MRK

117.85

-1.53%↓

LLY

885.52

+0.86%↑

JNJ

242.36

+0.87%↑

ABBV

213.25

+1.7%↑

NVS

150.37

+1.43%↑

MRK

117.85

-1.53%↓

LLY

885.52

+0.86%↑

JNJ

242.36

+0.87%↑

ABBV

213.25

+1.7%↑

NVS

150.37

+1.43%↑

MRK

117.85

-1.53%↓

Начало・Списък с акции・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Отворен

СекторЗдравеопазване

17.86 -0.78

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

17.55

Максимум

18.03

Ключови измерители
By Trading Economics
Приходи	-14M -50M
Продажби	12M 128M
Марж на печалбата	-39.506
Служители	1,784
EBITDA	-17M -48M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+94.28% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-262M 1.9B
Предишно отваряне	18.64
Предишно затваряне	17.86

Настроения в новините

By Acuity

34%

66%

91 / 349 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

28.13 / 31.12 Подкрепа & съпротива

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.03.2026 г., 17:33 ч. UTC

Значими събития в новините

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27.03.2026 г., 17:00 ч. UTC

Значими събития в новините

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27.03.2026 г., 16:03 ч. UTC

Значими събития в новините

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

29.03.2026 г., 23:47 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Falls Amid Rising Inflation Fears -- Market Talk

29.03.2026 г., 23:46 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

29.03.2026 г., 23:35 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

29.03.2026 г., 23:23 ч. UTC

Пазарно говорене

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

29.03.2026 г., 22:34 ч. UTC

Пазарно говорене

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

29.03.2026 г., 22:09 ч. UTC

Пазарно говорене

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

29.03.2026 г., 21:06 ч. UTC

Пазарно говорене

Значими събития в новините

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

29.03.2026 г., 21:03 ч. UTC

Пазарно говорене

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

29.03.2026 г., 21:01 ч. UTC

Пазарно говорене

Значими събития в новините

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

29.03.2026 г., 09:30 ч. UTC

Придобивния, сливания и поглъщания

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

28.03.2026 г., 08:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.03.2026 г., 19:16 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27.03.2026 г., 19:07 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27.03.2026 г., 19:04 ч. UTC

Пазарно говорене

Gold Rises But Can't Finish the Week Positive -- Market Talk

27.03.2026 г., 19:03 ч. UTC

Пазарно говорене

Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

27.03.2026 г., 19:02 ч. UTC

Пазарно говорене

Значими събития в новините

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27.03.2026 г., 18:12 ч. UTC

Пазарно говорене

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27.03.2026 г., 17:36 ч. UTC

Значими събития в новините

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27.03.2026 г., 17:34 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27.03.2026 г., 17:29 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27.03.2026 г., 16:38 ч. UTC

Пазарно говорене

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27.03.2026 г., 16:32 ч. UTC

Пазарно говорене

Значими събития в новините

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27.03.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.03.2026 г., 15:43 ч. UTC

Пазарно говорене

Значими събития в новините

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27.03.2026 г., 15:25 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.03.2026 г., 15:25 ч. UTC

Пазарно говорене

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

94.28% нагоре

12-месечна прогноза

Среден 34.97 USD 94.28%

Висок 47 USD

Нисък 21.8 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Zai Lab Ltd ADR през последните 3 месеца.

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

91 / 349 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.